112 related articles for article (PubMed ID: 12856345)
1. Qualitative and quantitative assessments of HAART adherence of substance-abusing women.
Powell-Cope GM; White J; Henkelman EJ; Turner BJ
AIDS Care; 2003 Apr; 15(2):239-49. PubMed ID: 12856345
[TBL] [Abstract][Full Text] [Related]
2. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
[TBL] [Abstract][Full Text] [Related]
3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
4. Greater adherence to highly active antiretroviral therapy (HAART) between pregnant versus non-pregnant women living with HIV.
Zorrilla CD; Santiago LE; Knubson D; Liberatore K; Estronza G; Colón O; Acevedo M
Cell Mol Biol (Noisy-le-grand); 2003 Dec; 49(8):1187-92. PubMed ID: 14983985
[TBL] [Abstract][Full Text] [Related]
5. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
6. Utility of the Millon Behavioral Medicine Diagnostic (MBMD) to predict adherence to highly active antiretroviral therapy (HAART) medication regimens among HIV-positive men and women.
Cruess DG; Minor S; Antoni MH; Millon T
J Pers Assess; 2007 Dec; 89(3):277-90. PubMed ID: 18001228
[TBL] [Abstract][Full Text] [Related]
7. An examination of HIV/AIDS patients who have excellent adherence to HAART.
Malcolm SE; Ng JJ; Rosen RK; Stone VE
AIDS Care; 2003 Apr; 15(2):251-61. PubMed ID: 12856346
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting antiretroviral drug adherence among HIV/AIDS adult patients attending HIV/AIDS clinic at Moi Teaching and Referral Hospital, Eldoret, Kenya.
Talam NC; Gatongi P; Rotich J; Kimaiyo S
East Afr J Public Health; 2008 Aug; 5(2):74-8. PubMed ID: 19024414
[TBL] [Abstract][Full Text] [Related]
9. A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment.
Andrade AS; McGruder HF; Wu AW; Celano SA; Skolasky RL; Selnes OA; Huang IC; McArthur JC
Clin Infect Dis; 2005 Sep; 41(6):875-82. PubMed ID: 16107989
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral treatment adherence and its correlates in Addis Ababa, Ethiopia.
Tadios Y; Davey G
Ethiop Med J; 2006 Jul; 44(3):237-44. PubMed ID: 17447389
[TBL] [Abstract][Full Text] [Related]
11. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data.
Protopopescu C; Raffi F; Roux P; Reynes J; Dellamonica P; Spire B; Leport C; Carrieri MP;
J Antimicrob Chemother; 2009 Sep; 64(3):599-606. PubMed ID: 19602563
[TBL] [Abstract][Full Text] [Related]
13. Predictors of antiretroviral adherence.
Murphy DA; Marelich WD; Hoffman D; Steers WN
AIDS Care; 2004 May; 16(4):471-84. PubMed ID: 15203415
[TBL] [Abstract][Full Text] [Related]
14. Barriers and successful strategies to antiretroviral adherence among HIV-infected monolingual Spanish-speaking patients.
Murphy DA; Roberts KJ; Hoffman D; Molina A; Lu MC
AIDS Care; 2003 Apr; 15(2):217-30. PubMed ID: 12856343
[TBL] [Abstract][Full Text] [Related]
15. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
Roux P; Carrieri MP; Villes V; Dellamonica P; Poizot-Martin I; Ravaux I; Spire B;
Addiction; 2008 Nov; 103(11):1828-36. PubMed ID: 18778390
[TBL] [Abstract][Full Text] [Related]
16. HAART with didanosine once versus twice daily: adherence and efficacy.
Roca B; Lapuebla C; Vidal-Tegedor B
Int J Infect Dis; 2005 Jul; 9(4):195-200. PubMed ID: 15964537
[TBL] [Abstract][Full Text] [Related]
17. Medication adherence for HIV positive women caring for children: in their own words.
Wood SA; Tobias C; McCree J
AIDS Care; 2004 Oct; 16(7):909-13. PubMed ID: 15385246
[TBL] [Abstract][Full Text] [Related]
18. Adherence to HAART among patients with HIV: breakthroughs and barriers.
Ickovics JR; Meade CS
AIDS Care; 2002 Jun; 14(3):309-18. PubMed ID: 12042076
[TBL] [Abstract][Full Text] [Related]
19. Gender and other psychosocial factors as predictors of adherence to highly active antiretroviral therapy (HAART) in adults with comorbid HIV/AIDS, psychiatric and substance-related disorder.
Applebaum AJ; Richardson MA; Brady SM; Brief DJ; Keane TM
AIDS Behav; 2009 Feb; 13(1):60-5. PubMed ID: 18690532
[TBL] [Abstract][Full Text] [Related]
20. Integrating adherence to highly active antiretroviral therapy into children's daily lives: a qualitative study.
Hammami N; Nöstlinger C; Hoerée T; Lefèvre P; Jonckheer T; Kolsteren P
Pediatrics; 2004 Nov; 114(5):e591-7. PubMed ID: 15520091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
